Huntingtin Aggregates in the Olfactory Bulb in Huntington's Disease

被引:19
|
作者
Highet, Blake [1 ,2 ]
Dieriks, Birger Victor [1 ,2 ]
Murray, Helen C. [1 ,2 ]
Faull, Richard L. M. [1 ,2 ]
Curtis, Maurice A. [1 ,2 ]
机构
[1] Univ Auckland, Fac Med & Hlth Sci, Dept Anat & Med Imaging, Auckland, New Zealand
[2] Univ Auckland, Fac Med & Hlth Sci, Ctr Brain Res, Auckland, New Zealand
来源
关键词
Huntington's disease; olfactory bulb; anterior olfactory nucleus; huntingtin aggregates; tau; ALZHEIMERS-DISEASE; TRINUCLEOTIDE REPEAT; LATE ONSET; IMPAIRMENTS; COEXISTENCE; MEMORY; MOTOR; GENE;
D O I
10.3389/fnagi.2020.00261
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Olfactory deficits are an early and prevalent non-motor symptom of Huntington's disease (HD). In other neurodegenerative diseases where olfactory deficits occur, such as Alzheimer's disease and Parkinson's disease, pathological protein aggregates (tau, beta-amyloid, alpha-synuclein) accumulate in the anterior olfactory nucleus (AON) of the olfactory bulb (OFB). Therefore, in this study we determined whether aggregates are also present in HD OFBs; 13 HD and five normal human OFBs were stained for mutant huntingtin (mHtt), tau, beta-amyloid, TDP-43, and alpha-synuclein. Our results show that mHtt aggregates detected with 1F8 antibody are present within all HD OFBs, and mHtt aggregate load in the OFB does not correlate with Vonsattel grading scores. The majority of the aggregates were located in the AON and in similar abundance in each anatomical segment of the AON. No mHtt aggregates were found in controls; 31% of HD cases also contained tau neurofibrillary tangles within the AON. This work demonstrates HD pathology in the OFB and indicates that disease-specific protein aggregation in the AON is a common feature of neurodegenerative diseases that show olfactory deficits.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Huntingtin aggregates may not predict neuronal death in Huntington's disease
    Kuemmerle, S
    Gutekunst, CA
    Klein, AM
    Li, XJ
    Li, SH
    Beal, MF
    Hersch, SM
    Ferrante, RJ
    ANNALS OF NEUROLOGY, 1999, 46 (06) : 842 - 849
  • [2] Association of Corticobasal Degeneration and Huntington's Disease: Can Tau Aggregates Protect Huntingtin Toxicity?
    Caparros-Lefebvre, Dominique
    Kerdraon, Olivier
    Devos, David
    Dhaenens, C. M.
    Blum, David
    Maurage, C. A.
    Delacourte, Andre
    Sablonniere, Bernard
    MOVEMENT DISORDERS, 2009, 24 (07) : 1089 - 1090
  • [3] Huntingtin aggregation and toxicity in Huntington's disease
    Bates, G
    LANCET, 2003, 361 (9369): : 1642 - 1644
  • [4] Normal huntingtin function in Huntington's disease
    Cattaneo, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 13 - 13
  • [5] HUNTINGTON'S DISEASE Flipping a switch on huntingtin
    Greiner, Erin R.
    Yang, X. William
    NATURE CHEMICAL BIOLOGY, 2011, 7 (07) : 412 - 415
  • [6] Nucleocytoplasmic transport of huntingtin and Huntington's disease
    Truant, R
    CLINICAL NEUROSCIENCE RESEARCH, 2003, 3 (03) : 157 - 164
  • [7] Subcellular Localization And Formation Of Huntingtin Aggregates Correlates With Symptom Onset And Progression In A Huntington'S Disease Model
    Landles, Christian
    Milton, Rebecca E.
    Ali, Nadira
    Flomen, Rachel
    Flower, Michael
    Schindler, Franziska
    Gomez-Paredes, Casandra
    Bondulich, Marie K.
    Osborne, Georgina F.
    Goodwin, Daniel
    Salsbury, Grace
    Benn, Caroline L.
    Sathasivam, Kirupa
    Smith, Edward J.
    Tabrizi, Sarah J.
    Wanker, Erich E.
    Bates, Gillian P.
    BRAIN COMMUNICATIONS, 2020, 2 (02)
  • [8] The olfactory bulb in Alzheimer’s disease
    Imre Kovács
    I. Török
    J. Zombori
    H. Yamaguchi
    Acta Biologica Hungarica, 1998, 49 (1): : 29 - 42
  • [9] The olfactory bulb in Alzheimer's disease
    Kovács, I
    Török, I
    Zombori, J
    Yamaguchi, H
    ACTA BIOLOGICA HUNGARICA, 1998, 49 (01): : 29 - 42
  • [10] Huntingtin-lowering strategies for Huntington's disease
    Barker, Roger A.
    Fujimaki, Motoki
    Rogers, Priya
    Rubinsztein, David C.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (10) : 1125 - 1132